Adagio Medical closes SPAC merger with $84.2M in financing; reports H1 2024 net loss of $14.5M

Adagio Medical Holdings, Inc.

Business combination with ARYA Sciences Acquisition Corp IV closed on July 31, 2024, providing ~$84.2 million in financing.
Transaction costs corrected to ~$13.1 million, including $1M payoff of SVB Term Loan.
Adagio Medical's H1 2024 revenue $280,000; net loss $14.5 million; cash $2.0 million as of June 30, 2024.
Working capital deficit of $58.0 million at June 30, 2024; going concern doubt alleviated by merger closing.
Adagio issued $15.5 million in convertible notes during H1 2024; converted 207,902 preferred shares for pre-funded warrants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.